

PROVIDING FOR CONSIDERATION OF H.R. 2427,
PHARMACEUTICAL MARKET ACCESS ACT OF 2003

JULY 24 (legislative day of JULY 23), 2003.—Referred to the House Calendar and
ordered to be printed

Mr. SESSIONS, from the Committee on Rules,
submitted the following

R E P O R T

[To accompany H. Res. 335]

The Committee on Rules, having had under consideration House Resolution 335, by a nonrecord vote, report the same to the House with the recommendation that the resolution be adopted.

SUMMARY OF PROVISIONS OF THE RESOLUTION

The resolution provides for consideration in the House of H.R. 2427, the Pharmaceutical Market Access Act of 2003, under a closed rule. The rule provides one hour of debate equally divided and controlled by the chairman and ranking minority member of the Committee on Energy and Commerce, or their designees. The rule waives all points of order against consideration of the bill and provides one motion to recommit.

The rule further provides that during consideration of the bill, notwithstanding the operation of the previous question, the Chair may postpone further consideration of the bill to a time designated by the Speaker.

COMMITTEE VOTES

Pursuant to clause 3(b) of House rule XIII the results of each record vote on an amendment or motion to report, together with the names of those voting for and against, are printed below:

Rules Committee record vote No. 178

Date: July 23, 2003.

Measure: H.R. 2427, Pharmaceutical Market Access Act of 2003.

Motion by: Mr. Frost.

Summary of motion: To make in order and provide the appropriate waivers for the amendment offered by Representative Emer-

son which allows the Secretary of HHS to create a Canada-only demonstration project wherein pharmacists and wholesalers could “re-import” FDA-approved prescription medications manufactured in FDA-approved facilities back into the U.S.

Results: Defeated 4 to 8.

Vote by Members: Goss—Nay; Linder—Nay; Pryce—Nay; Diaz-Balart—Nay; Myrick—Nay; Sessions—Nay; Reynolds—Nay; Frost—Yea; Slaughter—Yea; McGovern—Yea; Hastings (FL)—Yea; Dreier—Nay.

Rules Committee record vote No. 179

Date: July 23, 2003.

Measure: H.R. 2427, Pharmaceutical Market Access Act of 2003.

Motion by: Mrs. Slaughter.

Summary of motion: To report an open rule.

Results: Defeated 4 to 8.

Vote by Members: Goss—Nay; Linder—Nay; Pryce—Nay; Diaz-Balart—Nay; Myrick—Nay; Sessions—Nay; Reynolds—Nay; Frost—Yea; Slaughter—Yea; McGovern—Yea; Hastings (FL)—Yea; Dreier—Nay.

Rules Committee record vote No. 180

Date: July 23, 2003.

Measure: H.R. 2427, Pharmaceutical Market Access Act of 2003.

Motion by: Mr. McGovern.

Summary of motion: To increase the amount of general debate time to four hours.

Results: Defeated 4 to 8.

Vote by Members: Goss—Nay; Linder—Nay; Pryce—Nay; Diaz-Balart—Nay; Myrick—Nay; Sessions—Nay; Reynolds—Nay; Frost—Yea; Slaughter—Yea; McGovern—Yea; Hastings (FL)—Yea; Dreier—Nay.

Rules Committee record vote No. 181

Date: July 23, 2003.

Measure: H.R. 2427, Pharmaceutical Market Access Act of 2003.

Motion by: Mr. Hastings of Florida.

Summary of motion: To make in order and provide the appropriate waivers for the amendment offered by Representative Deutsch which requires the FDA to place one FDA official per 200,000 shipments (annual) of pharmaceuticals exported from wholesale/distributor warehouses to the U.S. These FDA officials will be required to keep records of daily, weekly, and monthly averages regarding type and quantity of drugs to be re-imported into the U.S.

Results: Defeated 4 to 8.

Vote by Members: Goss—Nay; Linder—Nay; Pryce—Nay; Diaz-Balart—Nay; Myrick—Nay; Sessions—Nay; Reynolds—Nay; Frost—Yea; Slaughter—Yea; McGovern—Yea; Hastings (FL)—Yea; Dreier—Nay.